Patents by Inventor Frank Y. Xie

Frank Y. Xie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110190375
    Abstract: The present invention provides nucleic acid molecules that inhibit c-Myc expression. Methods of using the nucleic acid molecules are also provided.
    Type: Application
    Filed: June 11, 2009
    Publication date: August 4, 2011
    Applicant: INTRADIGM CORPORATION
    Inventor: Frank Y. Xie
  • Publication number: 20110124710
    Abstract: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.
    Type: Application
    Filed: January 13, 2011
    Publication date: May 26, 2011
    Applicant: INTRADIGM CORPORATION
    Inventors: Yijia Liu, Patrick Y. Lu, Martin C. Woodle, Frank Y. Xie
  • Publication number: 20110105588
    Abstract: The present invention provides siRNA nucleic acid molecules that inhibit Notch1 expression. Methods of using the nucleic acid molecules are also provided.
    Type: Application
    Filed: March 12, 2009
    Publication date: May 5, 2011
    Applicant: INTRADIGM CORPORATION
    Inventors: Frank Y. Xie, Xiaodong Yang, Ying Liu
  • Publication number: 20110065644
    Abstract: The present invention provides siRNA nucleic acid molecules that inhibit PCSK9 or apolipoprotein B expression. Methods of using the nucleic acid molecules are also provided.
    Type: Application
    Filed: March 9, 2009
    Publication date: March 17, 2011
    Applicant: INTRADIGM CORPORATION
    Inventors: Frank Y. Xie, Xiaodong Yang, Ying Liu
  • Publication number: 20110053861
    Abstract: The present invention provides siRNA nucleic acid molecules that inhibit NF-kappaB expression. Methods of using the nucleic acid molecules are also provided.
    Type: Application
    Filed: March 12, 2009
    Publication date: March 3, 2011
    Applicant: INTRADIGM CORPORATION
    Inventors: Frank Y. Xie, Xiaodong Yang, Ying Liu
  • Publication number: 20110053862
    Abstract: The present invention provides siRNA nucleic acid molecules that inhibit survivin expression. Methods of using the nucleic acid molecules are also provided.
    Type: Application
    Filed: March 9, 2009
    Publication date: March 3, 2011
    Applicant: INTRADIGM CORPORATION
    Inventors: Frank Y. Xie, Xiaodong Yang, Ying Liu
  • Publication number: 20110046067
    Abstract: The present invention provides nucleic acid molecules that inhibit EGFR expression. Methods of using the nucleic acid molecules are also provided.
    Type: Application
    Filed: June 20, 2008
    Publication date: February 24, 2011
    Applicant: Intradigm Corporation
    Inventors: Xiaodong Yang, Frank Y. Xie, Yijia Liu, Ying Liu
  • Patent number: 7893244
    Abstract: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.
    Type: Grant
    Filed: February 8, 2008
    Date of Patent: February 22, 2011
    Assignee: Intradigm Corporation
    Inventors: Yijia Liu, Patrick Y. Lu, Martin C. Woodle, Frank Y. Xie
  • Patent number: 7893243
    Abstract: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.
    Type: Grant
    Filed: June 29, 2007
    Date of Patent: February 22, 2011
    Assignee: Intradigm Corporation
    Inventors: Yijia Liu, Patrick Y. Lu, Martin C. Woodle, Frank Y. Xie
  • Publication number: 20110038849
    Abstract: Compositions and methods for treating diseases, such as cancers. The compositions are effective to silence, down-regulate or suppress the expression of a validated target gene by stimulating the process of RNA interference of gene expression, thus inhibiting tumor growth. The invention also provides methods for treating diseases, such as cancers, by inactivation of a validated target gene product, using neutralizing antibody or small molecule drug, to inhibit tumor growth. More particularly, the compositions and methods are directed toward a cancer or a precancerous growth in a mammal, associated with pathological expression of a certain target genes identified herein. The compositions inhibit expression of the target gene when introduced into a tissue of the mammal. The methods include administering the compositions of the invention to a subject in need thereof in an amount effective to inhibit expression of a target gene in a cancerous tissue or organ.
    Type: Application
    Filed: December 21, 2006
    Publication date: February 17, 2011
    Applicant: Intradigm Corporation
    Inventors: Frank Y. Xie, Patrick Y. Lu, Martin C. Woodle, Yijia Liu
  • Publication number: 20110015249
    Abstract: The present invention provides nucleic acid molecules that modulate the expression of molecules in the angiopoietin/Tie2 signaling pathway. Methods of using the nucleic acid molecules are also provided.
    Type: Application
    Filed: July 3, 2008
    Publication date: January 20, 2011
    Inventors: Frank Y. Xie, Xiaodong Yang, Yijia Liu, Qing Zhou
  • Publication number: 20100298409
    Abstract: The present invention provides nucleic acid molecules that inhibit STAT3 expression. Methods of using the nucleic acid molecules are also provided.
    Type: Application
    Filed: September 17, 2008
    Publication date: November 25, 2010
    Applicant: INTRADIGM CORPORATION
    Inventors: Frank Y. Xie, Xiaodong Yang, Ying Liu
  • Publication number: 20100286241
    Abstract: The present invention provides nucleic acid molecules that inhibit K-ras expression. Methods of using the nucleic acid molecules are also provided.
    Type: Application
    Filed: September 18, 2008
    Publication date: November 11, 2010
    Applicant: INTRADIGM CORPORATION
    Inventors: Frank Y. Xie, Xiaodong Yang, Ying Liu
  • Publication number: 20100280097
    Abstract: The present invention provides nucleic acid molecules that inhibit HIF-1? expression. Methods of using the nucleic acid molecules are also provided.
    Type: Application
    Filed: September 18, 2008
    Publication date: November 4, 2010
    Applicant: INTRADIGM CORPORATION
    Inventor: Frank Y. Xie
  • Publication number: 20100279919
    Abstract: The present invention provides nucleic acid molecules that inhibit ILK expression. Methods of using the nucleic acid molecules are also provided.
    Type: Application
    Filed: September 4, 2008
    Publication date: November 4, 2010
    Applicant: INTRADIGM CORPORATION
    Inventor: Frank Y. Xie
  • Publication number: 20100273858
    Abstract: The present invention provides nucleic acid molecules that inhibit STAT5 expression. Methods of using the nucleic acid molecules are also provided.
    Type: Application
    Filed: September 17, 2008
    Publication date: October 28, 2010
    Applicant: INTRADIGM CORPORATION
    Inventors: Frank Y. Xie, Xiaodong Yang, Ying Liu
  • Patent number: 7786092
    Abstract: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.
    Type: Grant
    Filed: April 9, 2009
    Date of Patent: August 31, 2010
    Assignee: Intradigm Corporation
    Inventors: Yijia Liu, Patrick Y. Lu, Martin C. Woodle, Frank Y. Xie
  • Patent number: 7781414
    Abstract: The present invention relates to methods for treating cancers by manipulating a target gene expression by up-regulation, silencing and/or down-regulation of the gene, such as EGFR-RP, TRA1, MFGE8, TNFSF13 and ZFP236, respectively. The methods are useful in treating cancers and/or inhibiting tumor growth by enhancing expression of a gene that is validated as a target such as ICT1030, for protein, peptide drug and gene therapy modalities; or by RNA interference to silence and/or down-regulate targets such as ICT1024, ICT1025 and ICT1031 and ICB1003 that are validated for antibody, small molecule and other inhibitor drug modalities.
    Type: Grant
    Filed: April 1, 2004
    Date of Patent: August 24, 2010
    Assignee: Intradigm Corporation
    Inventors: Patrick Y. Lu, Frank Y. Xie, Martin C. Woodle, Yijia Liu, Quinn Q. Tang, Jun Xu
  • Publication number: 20100210710
    Abstract: The invention relates to nucleic acid molecule compositions for use in modulating the expression and activity of VEGF pathway genes and decreasing unwanted neovascularization, including tumor angiogenesis, by RNA interference and methods and compositions comprising the nucleic acid molecules.
    Type: Application
    Filed: October 10, 2008
    Publication date: August 19, 2010
    Applicant: INTRADIGM CORPORATION
    Inventors: Frank Y. Xie, Yijia Liu, Xiaodong Yang
  • Publication number: 20100203036
    Abstract: The present invention relates to methods for treating cancers by manipulating a target gene expression by up-regulation, silencing and/or down-regulation of the gene, such as EGFR-RP, TRA1, MFGE8, TNFSF13 and ZFP236, respectively. The methods are useful in treating cancers and/or inhibiting tumor growth by enhancing expression of a gene that is validated as a target such as ICT1030, for protein, peptide drug and gene therapy modalities; or by RNA interference to silence and/or down-regulate targets such as ICT1024, ICT1025 and ICT1031 and ICB1003 that are validated for antibody, small molecule and other inhibitor drug modalities.
    Type: Application
    Filed: December 29, 2009
    Publication date: August 12, 2010
    Applicant: INTRADIGM CORPORATION
    Inventors: PATRICK Y. LU, FRANK Y. XIE, MARTIN C. WOODLE, YIJIA LIU, QUINN Q. TANG, JUN XU